Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.
Its recent patent adds to several for cryogenic storage that works in tandem with server farms.
Using fake data is “not a panacea” to the security woes these models face.
Despite the buzz, the promises of this tech may be “underhyped,” one expert said.